Belite Bio (NASDAQ:BLTE – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.09), MarketWatch Earnings reports.
Belite Bio Stock Performance
Belite Bio stock traded down $0.77 during midday trading on Wednesday, reaching $37.11. 11,317 shares of the stock traded hands, compared to its average volume of 57,988. The company has a 50-day simple moving average of $33.78 and a two-hundred day simple moving average of $25.61. Belite Bio has a 12-month low of $11.00 and a 12-month high of $40.60.
Hedge Funds Weigh In On Belite Bio
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. UBS Group AG boosted its holdings in Belite Bio by 194.3% during the 3rd quarter. UBS Group AG now owns 883 shares of the company’s stock valued at $28,000 after acquiring an additional 583 shares during the period. State Street Corp boosted its stake in shares of Belite Bio by 7.4% in the 2nd quarter. State Street Corp now owns 13,385 shares of the company’s stock valued at $189,000 after buying an additional 921 shares during the period. Alps Advisors Inc. purchased a new position in shares of Belite Bio in the 4th quarter valued at about $492,000. Finally, Millennium Management LLC purchased a new position in shares of Belite Bio in the 2nd quarter valued at about $280,000. 3.82% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
About Belite Bio
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients.
- Five stocks we like better than Belite Bio
- How to Buy Metaverse Stock Step by Step
- 5 must-have next-gen technologies that institutions are buying
- What Investors Need to Know to Beat the Market
- 3 intriguing late-week earnings plays for short-term traders
- How to Invest in the Best Canadian Stocks
- Datadog is about to hit 52-week highs, and there’s more to come
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.